Sage Therapeutics, Inc. (SAGE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Barry E. Greene | President, CEO & Director | 1.28M | -- | 1963 |
| Mr. Christopher Benecchi | COO & Treasurer | 757.8k | -- | 1972 |
| Mr. Gregory Shiferman | Senior VP, General Counsel & Secretary | 617.35k | -- | -- |
| Mr. Michael Quirk Ph.D. | Chief Scientific Officer & Interim Head of R&D | -- | -- | -- |
| Ms. Ashley Kaplowitz | Director of Investor Relations | -- | -- | -- |
| Ms. Pamela Herbster | Senior VP and Chief People & Experience Officer | -- | -- | -- |
| Dr. Helen Colquhoun | Senior Vice President of Drug Safety & Pharmacovigilance | -- | -- | -- |
| Ms. Vanessa Procter | Senior Vice President of Corporate Affairs | -- | -- | -- |
| Dr. Aaron Koenig M.D. | Medical Director of Early Clinical Development | -- | -- | -- |
| Mr. Jeff Boyle | Investor Contact | -- | -- | -- |
Sage Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 353
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
July 29, 2025 at 10:59 AM UTC - August 4, 2025 at 12:00 PM UTC
Sage Therapeutics, Inc. Earnings Date